- Daily Industry Report
- Posts
- Daily Industry Report - September 8
Daily Industry Report - September 8

Your summary of the Voluntary and Healthcare Industry’s most relevant and breaking news; brought to you by the Health & Voluntary Benefits Association®
Jake Velie, CPT | Robert S. Shestack, CCSS, CVBS, CFF |
How Much Is the No Surprises Act Costing the U.S. Health Care System?
By Wendell Potter – The No Surprises Act solved a very real patient problem. Before the law took effect in 2022, a patient could do almost everything “right” — choose an in-network hospital, use insurance, seek emergency care — and still receive an out-of-network bill from a doctor or another clinician the patient never meaningfully chose. The law largely moved that fight away from the patient. In most cases, patients are now protected from surprise out-of-network balance billing and pay the cost-sharing they would have owed for in-network care. Read Full Article...
HVBA Article Summary
A high-profile cost estimate is driving debate, but it rests on assumptions: The article describes a Georgetown University Center on Health Insurance Reforms analysis that estimates the IDR system generated $22.4 billion in costs from 2022 through 2025. It breaks that estimate into components tied to above-benchmark payment awards, internal administrative costs, and fees paid to administer arbitration. The piece emphasizes that the total is an estimate rather than an itemized government accounting, and notes that some elements depend on assumed per-dispute administrative costs because actual internal costs are not directly reported.
IDR volume and outcomes have diverged sharply from early expectations: Federal officials initially modeled about 22,000 disputes per year, but the article says providers initiated roughly 2.6 million disputes in 2025 and that the trend continued into the first half of 2026. It also reports that providers won about 85% of disputes decided in 2025, contributing to insurer dissatisfaction with the system’s results. The article frames this gap between design assumptions and observed usage as evidence of a structural problem that may require policy attention regardless of which side is blamed.
The “qualifying payment amount” benchmark is central and now legally challenged, complicating cost claims: The piece explains that many arguments about whether IDR is “costly” hinge on the qualifying payment amount (QPA), an insurer-calculated median in-network rate used as a key reference in arbitration. It cites pushback from physician groups that argue QPAs are often inaccurate, unreasonably low, and difficult for physicians to independently verify, and it notes the Fifth Circuit’s en banc decision in Texas Medical Association v. HHS (TMA III) that found aspects of the QPA methodology unlawful and required insurers to recalculate. The article argues that cost estimates relying on pre-TMA III QPAs may be measuring against a baseline that regulators must redo, and suggests recalculating costs under a revised QPA before drawing firm conclusions about the law’s net impact.
HVBA Poll Question - Please share your insightsWhat should be the top priority for improving the No Surprises Act’s dispute resolution process? |
Our last poll results are in!
27.45%
Of the Daily Industry Report readers who participated in our last polling question, when asked: “When a high-cost specialty drug or infusion claim hits your plan, what happens first?” reported, “We do not usually see it until after payment.”
There was a tie in responses with 25.27% of DIR respondents responding “We review lower-cost options immediately,” and 25.27% reporting “We need a better strategy before the claim hits.” The remaining 22.01% “rely on the PBM or carrier to manage when a high-cost specialty drug or infusion claim hits their plan.” Thank you to National Integrative Health for powering this polling question.
Have a poll question you’d like to suggest? Let us know!
6 payer reimbursement changes to know in September
By Jakob Emerson – Several of the nation’s largest health insurers rolled out reimbursement policy changes Sept. 1, ranging from new lab testing coverage limits at UnitedHealthcare to a billing overhaul at Blue Cross Blue Shield of Michigan that has drawn pushback from providers. Read Full Article...
HVBA Article Summary
UnitedHealthcare adds new limits and exclusions for several lab-testing categories: The insurer outlined new reimbursement policies spanning its commercial, Medicare Advantage, exchange, and Medicaid plans, with most changes beginning Sept. 1 and some Medicaid timing varying by state. The updates include caps on specific types of testing and limits on how frequently certain assays can be reimbursed. UnitedHealthcare also described an update to its exchange-plan genetic testing policy for neurological disorders, including changes tied to clinical evidence and billing codes.
Aetna expands claims-editing efforts and reduces payment for certain CT-related radiology billing: Aetna said it is broadening its Claim and Code Review Program by adding new edits informed by CMS, AMA CPT, and evidence-based guidelines. Separately, it plans a payment reduction for radiology services billed with modifier CT when the equipment does not meet NEMA “Smart Dose” standards. The policy applies to the technical component (and the technical portion of global billing) and is described as aligning with CMS guidance.
Multiple Blue Cross plans describe payment-policy revisions affecting billing practices and surgery/lab reimbursement: Blue Cross Blue Shield of Michigan announced a phased approach to end incident-to billing, including new modifier requirements and future reimbursement reductions for continued incident-to use. BCBS Texas posted updates to numerous lab-related reimbursement policies across a wide range of test types. BCBS North Carolina said it will change how it reimburses multiple and bilateral surgeries, including a tiered reduction approach for outpatient facility claims and a revised schedule for professional claims.
Biosimilars can help employers get autoimmune drug costs under control
By Marium Mesia – Targeted immunomodulators have changed care for patients with autoimmune and inflammatory conditions like rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. These therapies can reduce symptoms, prevent disease progression and improve quality of life, but they're one of the most expensive categories of products in pharmacy benefits. That tension has made TIMs a practical test case for biosimilars: Can plans encourage patients to move to lower-cost alternatives from the original "reference products" without disrupting care? Read Full Article... (Subscription required)
HVBA Article Summary
Adalimumab biosimilars and formulary changes: The article describes how adalimumab (with Humira as the reference product) was a common starting therapy among the targeted immunomodulators used by the studied patients. It reports that biosimilars became the majority of first fills and reached complete uptake after Humira was removed from plan formularies. The piece frames this as evidence that benefit design and coverage decisions can materially influence which products patients start on. It also notes that, in this dataset, adoption did not appear to require extensive medication changes for most patients.
Continuity of care and persistence matter in biosimilar transitions: The article emphasizes persistence—whether patients continue therapy—as a key metric when moving from reference biologics to biosimilars. It reports that a specialty pharmacy helped guide patients through the transition process and that about 63% of the 472 patients kept using targeted immunomodulator therapy after the first fill. The discussion highlights why plan sponsors should monitor whether patients can stay on therapy without disruptive switching. It positions persistence and switching behavior as central to judging whether a biosimilar strategy is working clinically, not just financially.
Savings aren’t the only outcome; safety and patient costs require monitoring: The article cautions that cost should not be the sole consideration because targeted immunomodulators can increase infection risk and may stop working over time for some patients. It cites outside research (including Clinical Microbiology Reviews, BMJ Medicine, and JAMA) to underline the need for monitoring and rapid response when complications or loss of response occur. It also notes that biosimilar competition does not necessarily translate into lower out-of-pocket spending for patients, referencing a JAMA Health Forum study. The article recommends evaluating biosimilar strategies with multiple measures beyond ingredient cost, including adoption, net plan cost, member cost-sharing, persistence, and switching.
Health insurer CEO: ‘Make prior authorization illegal’
By Jakob Emerson – Earlier this year, health insurance plans covering older adults, low-income people and ACA marketplace enrollees were required to officially begin publicly sharing how often they deny prior authorization requests, and how often those denials are overturned after they’re appealed. And although all that data is now filtering out to consumers in an easily digestible format, the numbers don’t come close to telling the full story of just how big of a problem prior authorization might be. Read Full Article...
HVBA Article Summary
New reporting increases visibility but has major context gaps: The article explains that health plans in Medicare Advantage, Medicaid managed care, and the ACA marketplaces have begun publicly reporting prior-authorization denial and appeal outcomes. However, the reported metrics do not specify which services are denied or the rationale behind denials, which limits how consumers interpret the data. The piece also notes that the reporting approach does not enable consistent, apples-to-apples comparisons across insurers.
Denial percentages may not reflect real-world impact across plans and populations: The story highlights that reporting focuses on percentages rather than raw volumes, so a plan with a low denial rate could still deny a large number of requests if it has many members. It also points out that “gold carding” programs that exempt certain providers from prior authorization can alter what ends up being measured. In addition, the roughly 150 million Americans insured through employer-sponsored coverage are not included in these public datasets, and no federal proposal is described as requiring those numbers to be disclosed.
Policy and industry responses range from process improvements to calls for a ban: The article describes CMS proposing to broaden reporting to include prescription drugs and implementing requirements for electronic prior-authorization workflows and electronic patient access to prior-auth and claims information. It also notes a Trump-era voluntary pledge by insurers to simplify prior authorization and industry claims of reductions, while emphasizing that underlying methodology was not publicly shared. Separately, an advocacy group’s policy brief argues for an outright ban on prior authorization as currently practiced, citing administrative burden estimates and framing the practice as profit-driven rather than patient-protective.
What 30 years in HR taught me about healthcare costs and employee trust
By Stephanie Porrino – After more than three decades in HR, I’ve come to accept that not everything we’ve always done deserves to stick around. Big hair, perms, shoulder pads and fax machines at one point were everywhere. Then we moved on, for the most part. In many ways, healthcare benefits still feel stuck in the past. We spent years focused on access to care. Now the real question is whether employees and their families can afford to use it. Rising healthcare costs have become so routine that we barely question them anymore. Premiums go up every year, deductibles quietly climb, and out of pocket maximums stretch further out of reach. Read Full Article... (Subscription required)
HVBA Article Summary
Rising Costs Are Increasing Pressure on Employers and Employees: Out-of-pocket maximums have climbed as high as $8,500 for single coverage, while employers continue to face annual healthcare cost increases that many CFOs consider unsustainable above 6%. Higher deductibles and cost sharing can make employees more hesitant to use their benefits, with an Imagine360 survey finding that nearly half of employees who delayed or skipped care because of costs said their condition worsened. As healthcare costs are projected to rise nearly 10%, employers face the challenge of controlling spending without shifting an unsustainable financial burden to employees.
Traditional Plan Designs May Not Fully Address Affordability and Usability: PPOs were originally designed to improve access and provider choice, but the article argues that access alone does not address employees’ growing concerns about affordability, billing uncertainty, and navigating care. Traditional approaches such as increasing cost sharing, adjusting plan designs, and renegotiating renewals may provide short-term financial relief but can also make coverage more complicated or expensive for employees to use. This has led some employers to evaluate whether existing plan structures remain appropriate as healthcare costs and workforce expectations evolve.
Alternative Health Plans Are Presented as Another Approach to Cost and Access: The author describes alternative health plans paired with direct primary care as a potential way to provide greater upfront cost clarity, navigation support, easier access to primary care, and savings for employers. By reducing financial and administrative barriers, these models may encourage employees to seek preventive and primary care earlier while potentially allowing employers to reinvest savings in wages, benefits, or other workforce initiatives. The article encourages HR leaders to evaluate both traditional and alternative models carefully and take an active fiduciary role in determining how healthcare decisions affect employees and organizational costs.
Smart ring maker Oura files to go public, pitching investors on AI-driven preventive health
By Heather Landi – Oura, the smart ring maker and health tracking company, filed to go public on Thursday to fuel its next phase of growth as it aims to build an artificial intelligence-powered health platform. The company has not specified the number of shares to be offered or the price range for the proposed offering. Oura intends to list on the Nasdaq under the ticker symbol “OURA.” Founded in Finland in 2013, Oura's smart rings continuously track more than 50 health metrics, including heart rate, sleep, daily movement and activity, stress, fertility windows and metabolic health. The company filed confidentially for an initial public offering in May. Read Full Article...
HVBA Article Summary
IPO positioning and strategy: Oura’s filing emphasizes a shift in narrative from being primarily a smart-ring hardware company to becoming an AI-driven health platform. The company highlights recurring subscription revenue, consumer engagement, and a proprietary data asset as central to the investment thesis. It also frames its long-term opportunity around preventive healthcare rather than only consumer wellness. The company says the offering is intended to support its next phase of growth, while leaving key IPO terms (share count and price range) unspecified.
Financial scale and operating performance: In its S-1, Oura reports rapid growth in the first nine months of 2026 compared to the same period in 2025, including a 74% year-over-year increase in revenue to $1.2 billion. It also reports profitability metrics for the nine months ended June 30, 2026, including 55% gross margins, net income of $61 million, and adjusted EBITDA of $107 million. The mix includes both hardware and membership revenue, with hardware still larger but subscriptions contributing meaningful dollars. The company also states trailing twelve-month revenue of more than $1.4 billion.
Membership behavior, data advantage, and ecosystem expansion: Oura reports 5 million paid members, with historically high conversion from ring activation to paid membership and roughly 85% 12-month retention, alongside an average of about 23 hours/day of wear time. The company says it has accumulated nearly 42 billion hours of longitudinal biometric data and argues this data helps improve AI-driven insights and supports a hard-to-replicate advantage. It also points to an API-first approach and integrations with more than 1,200 partners, spanning areas like fertility, metabolic health, and activity platforms. Separately, Oura describes increasing engagement with health plans and employers, including collaborations and benefit-style distribution arrangements.
The cost of ignoring long-term care
By Chuck Greenblott – Let me ask you something uncomfortable: When was the last time you brought up long-term care with a client? If you're like many agents, the answer is somewhere between "rarely" and "never." And that's understandable. For years, the LTC conversation was difficult, negative and overly complicated. It often felt like a topic you only brought up when a client asked — if you brought it up at all. Read Full Article...
HVBA Article Summary
Aging and care needs are becoming unavoidable planning topics: The article argues that long-term care is no longer a niche or optional discussion because clients are steadily aging and many will encounter a care event personally or within their family. It frames the central issue as preparedness: whether clients have a plan in place before a crisis forces decisions. The author positions the “blind spot” around long-term care as costly not only for clients, but also for agencies that fail to address it early.
Real-world costs and caregiver constraints are intensifying the pressure: The piece describes a demographic surge as baby boomers enter higher-need years while professional caregiver supply tightens and unpaid family caregivers experience burnout. It provides examples of current market pricing for different levels of care, emphasizing that these are present-day expenses families are already encountering. This environment, the author suggests, is raising client anxiety about maintaining independence and protecting accumulated assets.
Agencies can improve differentiation by initiating LTC conversations and partnering with specialists: The author contends that many clients signal long-term care concerns indirectly (e.g., worries about burdening children or staying at home), and advisors can stand out by recognizing and addressing those cues. The article argues that relying solely on life insurance riders may not equal dedicated long-term care planning and can leave clients with a false sense of preparedness. As a practical approach, it recommends that agencies start the conversation and collaborate with certified long-term care specialists when deeper product and underwriting expertise is needed, while maintaining the primary client relationship.
Not an ‘Easy Way Out’: Rethinking GLP-1 Stigma
By Yoni Freedhoff, MD – An opinion piece recently published in Nature’s International Journal of Obesity called for conceptual clarity around GLP-1s and treatment related stigma. Interested, I clicked through and laid out within was a cogent argument on how we need to consider the rise of GLP-1-related weight stigma as a real phenomenon worthy of attention. Read Full Article...
HVBA Article Summary
Stigma ties medication-assisted weight loss to perceived lack of effort: The article argues that some people view weight loss as something that should come from “effort, hard work, and discipline,” which can lead to negative judgments about those who use GLP-1 medications. In that framing, using medication can be interpreted as replacing willpower rather than treating a medical condition. The piece suggests this dynamic can create a no-win situation in which people are criticized both for using medication and for struggling without it.
Potential health and care consequences extend beyond hurt feelings: The author describes weight stigma as harmful rather than trivial, connecting it to impacts on mental health, physical health, eating disorders, and stress. The commentary also suggests GLP-1-related stigma could reduce willingness to start or stay on therapy by increasing shame and fear of judgment. It further raises the possibility that some patients might avoid medical visits or turn to less evidence-based approaches if they feel stigmatized for considering medication.
How stigma might evolve as obesity is treated like other chronic diseases: The article contrasts two outlooks: one that anticipates “quick-fix” stigma worsening over time and the author’s view that it may fade as society and clinicians increasingly see obesity as a chronic noncommunicable disease. The author compares this potential shift to how conditions such as hypertension are commonly treated with medication without blame. At the same time, the piece warns that even if stigma about using GLP-1s decreases, a new form of stigma could emerge toward people who do not or cannot take these medications.

Docs say medical misinformation is on the rise, but AI isn't behind it
By Sara Heath – Physicians increasingly say their patients are influenced by medical misinformation, but the culprit isn't AI as one might think. Rather, social media, influencers, news coverage and even government health agencies are impacting patients' understanding of health topics, according to a new survey from The Physician's Foundation, obtained via email. Patients are more susceptible to medical misinformation than ever before, with 31% of physician respondents saying their patients are influenced by falsehoods a great deal. Another 38% said their patients are at least moderately influenced by medical misinformation. Read Full Article...
HVBA Article Summary
AI is not cited as the primary driver of misinformation in this survey: While the article notes broader concern about patient overreliance on AI chatbots, surveyed physicians more often attributed misinformation to other channels. Only a minority said AI frequently contributes, and very few named AI chatbots as the biggest driver compared with other sources. The findings suggest the misinformation problem physicians encounter in practice is still dominated by more established information pathways rather than primarily by generative AI tools.
Social and information ecosystems are viewed as major sources of false health claims: Physicians most frequently pointed to social media, word of mouth and influencers as prominent contributors to misinformation. News coverage and search engines were also commonly described as perpetuating falsehoods. The survey additionally highlights that some physicians believe government health agencies can sometimes or very often spread misinformation, which the article frames as particularly concerning given their public role.
Misinformation is reported to strain care delivery and patient trust, but clinicians feel partially equipped to respond: Many physicians said misinformation affects their ability to provide quality care and is linked to issues like patient anxiety, nonadherence and refusal of recommended care. A notable share also reported that misinformation can contribute to breakdowns in patient-physician trust. At the same time, most physicians expressed confidence in identifying and correcting misinformation, but time constraints and patients’ limited online health literacy were described as key barriers.




